Kazuto Harada

Kazuto Harada

Auto-generated profile, based on publicly available information

Kazuto Harada

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RWRuiping Wang
Ruiping Wang
MDMinghao Dang
Minghao Dang
KHKazuto Harada
Kazuto Harada
GHGuangchun Han
Guangchun Han
FWFang Wang
Fang Wang
LWLinghua Wang
Linghua Wang

1 October 2020 in F1000Research
Verified
Journal Article
Open access
PDF file
KHKazuto Harada
Kazuto Harada
JRJane E. Rogers
Jane E. Rogers
MIMasaaki Iwatsuki
Masaaki Iwatsuki
KYKohei Yamashita
Kohei Yamashita
HBHideo Baba
Hideo Baba
Jaffer AjaniJaffer Ajani
Jaffer Ajani
Esophageal cancer (EC) is an aggressive malignancy with an increasing incidence and a poor prognosis. EC is histologically divided into two major categories: adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). EAC and ESCC are molecularly different and therefore treatments should reflect the respective histological subtype. Combined modality therapy is needed for localized EC. When EC is advanced (stage 4), systemic therapy is the mainstay treatment for palliation. For localized EC, several strategies are considered standard, and more trials are necessary to determine a unified and more effective approach. The management for advanced EC is slowly evolving as immunotherapy is showing some promise for ESCC, but more data from ongoing studies are anticipated. Treatment advances will be based on high-definition genomic investigation of individual tumors. Herein, we review the contemporary trends in diagnosing and treating EAC and ESCC.

14 August 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
TUTomoyuki Uchihara
Tomoyuki Uchihara
KMKeisuke Miyake
Keisuke Miyake
AYAtsuko Yonemura
Atsuko Yonemura
YKYoshihiro Komohara
Yoshihiro Komohara
RIRumi Itoyama
Rumi Itoyama
TITakatsugu Ishimoto
Takatsugu Ishimoto
Extracellular vesicles (EV) from cancer-associated fibroblasts (CAF) are composed of diverse payloads. Although CAFs impact the aggressive characteristics of gastric cancer cells, the contribution of CAF-EV to gastric cancer progression has not been elucidated. Here, we investigated the molecular mechanism of the changes in gastric cancer characteristics induced by CAF-EV. CAF abundance in gastric cancer tissues was associated with poor prognosis of patients with gastric cancer receiving chemotherapy. Moreover, CAF-EV induced tubular network formation and drug resistance of gastric cancer cells in the extracellular matrix (ECM). Comprehensive proteomic analysis of CAF-EV identified that Annexin A6 plays a pivotal role in network formation and drug resistance of gastric cancer cells in the ECM via activation of β1 integrin-focal adhesion kinase (FAK)-YAP. A peritoneal metastasis mouse model revealed that CAF-EV induced drug resistance in peritoneal tumors, and inhibition of FAK or YAP efficiently attenuated gastric cancer drug resistance in vitro and in vivo. These findings demonstrate that drug resistance is conferred by Annexin A6 in CAF-EV and provide a potential avenue for overcoming gastric cancer drug resistance through the inhibition of FAK-YAP signaling in combination with conventional chemotherapeutics. Significance: This study elucidates a novel molecular mechanism through which Annexin A6 in CAF-EV activates FAK-YAP by stabilizing β1 integrin at the cell surface of gastric cancer cells and subsequently induces drug resistance.

1 April 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
FLFan Li
Fan Li
YXYan Xu
Yan Xu
BLBovey Liu
Bovey Liu
PSPankaj Kumar Singh
Pankaj Kumar Singh
WZWei Zhao
Wei Zhao
Jaffer AjaniJaffer Ajani
Jaffer Ajani
Purpose: Esophageal cancer (EC) is a lethal disease that is often resistant to therapy. Alterations of YAP1 and CDK6 are frequent in EC. Deregulation of both molecules may be responsible for therapy resistance. Experimental Design: Expression of YAP1 and CDK6 were examined in EC cells and tissues using immunoblotting and immunohistochemistry. YAP1 expression was induced in EC cells to examine YAP1-mediated CDK6 activation and its association with radiation resistance. Pharmacological and genetic inhibitions of YAP1 and CDK6 were performed to dissect the mechanisms and assess the antitumor effects in vitro and in vivo. Results: YAP1 expression was positively associated with CDK6 expression in resistant EC tissues and cell lines. YAP1 overexpression upregulated CDK6 expression, transcription, and promoted radiation resistance; whereas treatment with the YAP1 inhibitor, CA3, strongly suppressed YAP1 and CDK6 overexpression, reduced Rb phosphorylation as well as sensitized radiation resistant/YAP1high EC cells to irradiation. CDK4/6 inhibitor, LEE011, and knock down of CDK6 inhibited expression of YAP1 and sensitized resistant EC cells to irradiation indicating a positive feed-forward regulation of YAP1 by CDK6. Additionally, suppression of both the YAP1 and CDK6 pathways by the combination of CA3 and LEE011 significantly reduced EC cell growth, CSC population (ALDH1+ and CD133+), sensitized cells to irradiation and showed a strong anti-tumor effect in vivo against radiation resistant EC cells. Conclusions: Our results document that a positive crosstalk of YAP1 and CDK6 confers radiation resistance to EC cells. Targeting both YAP1 and CDK6 pathways could be novel therapeutic strategies to overcome resistance in EC.

6 April 2016 in Oncology
Verified
Journal Article
Open access
PDF file
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
GNGraciela Nogueras
Graciela Nogueras
EEElena Elimova
Elena Elimova
RWRoopma Wadhwa
Roopma Wadhwa
HSHironori Shiozaki
Hironori Shiozaki
Jaffer AjaniJaffer Ajani
Jaffer Ajani
Background: Patients with localized gastric adenocarcinoma (LGAC), who get pre-operative therapy, have heterogeneous/unpredictable outcomes. Predictive clinical variables/biomarkers are not established. Methods: We analyzed 107 LGAC patients who had chemoradiation and surgery. LGACs were grouped for (1) presence/absence of signet ring cell histology (SRC) and (2) histologic grade: G2 or G3. %SRC was assessed (0, 1-10, 11-49, and 50-100%) and correlated with pathologic complete response (pathCR) or <pathCR in the resected specimens. Results: Most patients were men (60%), had stage cIII LGAC (50%), and received chemotherapy before chemoradiation (93%). Most had G3 tumors (78%) and SRC (58%). Presence of SRC was associated with a lower rate of pathCR (11 vs. 36%, p = 0.004), and the association remained significant even with a low percentage of SRC (1-10%; p = 0.014). The higher the fraction of SRC, the lower was the probability of pathCR (p = 0.03). G3 and SRC led to a shorter overall survival (OS) (p = 0.046 and p = 0.038, respectively). yp stage independently prognosticated OS and recurrence-free survival (p < 0.001). Conclusion: Our novel findings suggest that LGACs with SRC are relatively chemoradiation resistant compared to LGACs without SRC. A higher fraction of SRC is associated with higher resistance. Upon validation/biomarker(s) evaluation, reporting of the fraction of SRC may be warranted.

30 August 2018 in F1000Research
Verified
Journal Article
Open access
PDF file
KHKazuto Harada
Kazuto Harada
ALAnthony Lopez
Anthony Lopez
NSNamita Shanbhag
Namita Shanbhag
BBBrian Badgwell
Brian Badgwell
HBHideo Baba
Hideo Baba
Jaffer AjaniJaffer Ajani
Jaffer Ajani
Gastric adenocarcinoma (GAC) is one of the most aggressive malignancies and has a dismal prognosis. Therefore, multimodality therapies to include surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy are needed to provide advantage. For locally advanced GAC (>cT1B), the emerging strategies have included preoperative chemotherapy, postoperative adjuvant chemotherapy, and (occasionally) postoperative chemoradiation in various regions. Several novel therapies have been assessed in clinical trials, but only trastuzumab and ramucirumab (alone and in combination with paclitaxel) have shown overall survival advantage. Pembrolizumab has been approved by the US Food and Drug Administration on the basis of response rate only for patients with microsatellite instability (MSI-H) or if PD-L1 expression is positive (≥1% labeling index in tumor/immune cells in the presence of at least 100 tumor cells in the specimen). Nivolumab has been approved in Japan on the basis of a randomized trial showing significant survival advantage for patients who received nivolumab compared with placebo in the third or later lines of therapy. The cure rate of patients with localized GAC in the West is only about 40% and that for metastatic cancer is very poor (only 2–3%). At this stage, much more target discovery is needed through molecular profiling. Personalized therapy of patients with GAC remains a challenge.